Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01583543 · ClinicalTrials.gov registry record · Phase 2
Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT01583543: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT01583543 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01583543, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
This research study is a Phase II clinical trial to test the efficacy of Olaparib in adult participants with recurrent/metastatic Ewing's Sarcoma following failure of prior chemotherapy.
Interventions
- DRUG Olaparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2012-05 |
| Est. Completion | 2014-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01583543
The ClinicalTrials.gov registry entry for NCT01583543 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Olaparib is the first listed.
NCT01583543 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01583543 about?
NCT01583543 is a clinical study titled "Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma". This research study is a Phase II clinical trial to test the efficacy of Olaparib in adult participants with recurrent/metastatic Ewing's Sarcoma following failure of prior chemotherapy.
What is the current status of trial NCT01583543?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2012-05. Estimated completion is 2014-11.
What interventions are being tested in trial NCT01583543?
The interventions under investigation include: Olaparib (DRUG).
Who is sponsoring clinical trial NCT01583543?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.